---

Highlights of October 2019

1. India based Macleods Pharma inks Global drug license agreement with TB Alliance for approximately 140 countries and territories.
2. Biocon enters into licensing agreement with Just-Evotec Biologics for early-stage biosimilar asset.
3. Cipla acquires novel anti-infective AMR drug Elores from Venus Remedies. [Earlier Aagami supported Venus to out-license Elores to US and Canada]
4. Alexion inks deal to acquire Achillion for US$930 Million upfront.
5. Insilico signs US$200 Million AI drug discovery partnership with China's CTFH.
6. Roche pays US$200 Million for rights to Dicerna's hepatitis B RNAi drug.
7. Daiichi Sankyo has acquired two anti-hypertensive drugs and one antiemetic medication from Astellas Pharma under an asset purchase agreement for US$88.44 Million.
8. AngioDynamics acquires artery-clearing laser treatment from Eximo for US$66 Million.
9. Q BioMed has entered into an exclusive US distribution agreement with Jubilant Radiopharma for Metastron (strontium-89 chloride), a non-opioid metastatic cancer drug.
10. Neopharma has formed a joint venture in UAE with USA-based Elevar Therapeutics for TKI candidate.
11. GTX Medical and NeuroRecovery merge to push spinal cord implant for paralysis.
12. NSF International buys up CRO Amarex.

Updates at Aagami

• Aagami gets overbooked for meetings at BIO-Europe 2019 (Nov 11-13, Hamburg, Germany).
• Aagami partners with a Global Intellectual Property Research company to increase its focus in IP monetization and offer integrated IP Research/ Licensing/Sale solutions to global clientele.
• New Client Win: American film maker who innovated as a hobby for an unmet need for the benefit the society, especially for Old, infirm and indisposed, now seeks to out-license/ sell the IP with Aagami support
• Aagami to attend JP Morgan Healthcare Conference and Biotech Showcase (January 2020). Meetings calendar will open on November 25, 2019.